The Rise of Continuous Biological Monitoring
While laboratory biomarkers remain essential, they represent just one part of the overall aging picture. A revolution is underway in the world of wearable and point-of- care biosensing technology.
The previous generation of
wearables tracked step counts, estimated sleep duration, and provided basic heart rate metrics. Devices coming in 2026 offer something much more valuable: continuous insights into core physiological processes that forecast long-term health.
Continuous glucose monitors, once limited to diabetes management, now support metabolic optimization for the general population. Their quick adoption shows increasing awareness that metabolic dysfunction is at the core of accelerated aging. By tracking real-time responses to diet, exercise, stress, and sleep, these monitors help users address glycemic instability before it develops into chronic disease.
The technological frontier of biological monitoring continues to expand. New biosensing devices – worn on the skin or inserted microscopically beneath – will soon be able to monitor cortisol fluctuations, inflammatory proteins, mitochondrial metabolites, vascular responses, and markers of neurological stress. This data shows biological changes as they happen. The implications are significant: abnormalities can be detected before symptoms appear, and interventions can be administered before damage becomes permanent.
The convention of waiting for illness to arise will gradually be considered outdated. Ongoing biological monitoring will become a new norm for proactive healthcare.
The Precision Medicine Framework in Longevity
Longevity medicine is rapidly becoming synonymous with personalized care. Since no two people age the same way, their longevity programs should also differ. The use of advanced diagnostic panels plays a crucial role in supporting this trend.
One impactful innovation in this area is blood test panels that can reveal necessary information about a patient’s food sensitivities and gut/immune barrier. This panel includes testing for Candida, Zonulin, occludin, and lipopolysaccharides (LPS). By using immune reactivity assays, such as IgG 1–4 and complement activation (via the most stable molecular inflammatory molecule – C3d), clinicians can detect food sensitivities that lead to chronic inflammation. Adding IgA 1–2 markers indicates intestinal permeability, highlighting breakdowns in the mucosal barrier that weaken both immune defenses and metabolic functions.
continued on next page
21st Century Approach to Musculoskeletal Conditions
(Track 2) Presented by Dr. Robert Silverman
Saturday, Oct. 24, 2026 Part 1: 1:45 - 2:30 pm | Part 2: 4:00 - 4:45 pm
Ple x us July/A ugust 20 26 23
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32
